AU2022283272A1 - Methods for treating post infectious autoimmune diabetes - Google Patents

Methods for treating post infectious autoimmune diabetes Download PDF

Info

Publication number
AU2022283272A1
AU2022283272A1 AU2022283272A AU2022283272A AU2022283272A1 AU 2022283272 A1 AU2022283272 A1 AU 2022283272A1 AU 2022283272 A AU2022283272 A AU 2022283272A AU 2022283272 A AU2022283272 A AU 2022283272A AU 2022283272 A1 AU2022283272 A1 AU 2022283272A1
Authority
AU
Australia
Prior art keywords
day
teplizumab
dose
diabetes
course
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022283272A
Other languages
English (en)
Inventor
Francisco Leon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Provention Bio Inc
Original Assignee
Provention Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provention Bio Inc filed Critical Provention Bio Inc
Publication of AU2022283272A1 publication Critical patent/AU2022283272A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2022283272A 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes Pending AU2022283272A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163192414P 2021-05-24 2021-05-24
US63/192,414 2021-05-24
PCT/US2022/030780 WO2022251258A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes
US17/752,650 2022-05-24
US17/752,650 US20220372146A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes

Publications (1)

Publication Number Publication Date
AU2022283272A1 true AU2022283272A1 (en) 2023-12-07

Family

ID=84104472

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022283272A Pending AU2022283272A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes

Country Status (10)

Country Link
US (1) US20220372146A1 (https=)
EP (1) EP4347021A4 (https=)
JP (1) JP2024521164A (https=)
KR (1) KR20240023522A (https=)
CN (1) CN117794572A (https=)
AU (1) AU2022283272A1 (https=)
CA (1) CA3219473A1 (https=)
IL (1) IL308627A (https=)
MX (1) MX2023013849A (https=)
WO (1) WO2022251258A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
EP4532552A4 (en) * 2022-05-24 2025-10-22 Provention Bio Inc METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING TYPE 1 DIABETES
TW202506177A (zh) * 2023-03-30 2025-02-16 美商普泛森生技公司 減少外源性胰島素使用之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
SG177907A1 (en) * 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
WO2015073833A1 (en) * 2013-11-15 2015-05-21 Pharmacyclics, Inc. Methods for delaying or preventing the onset of type 1 diabetes
WO2020232247A1 (en) * 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CA3148179A1 (en) * 2019-08-20 2021-02-25 Bruce J. Mccreedy Jr. Lymphodepletion dosing regimens for cellular immunotherapies
IL298999A (en) * 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) * 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
EP4532552A4 (en) * 2022-05-24 2025-10-22 Provention Bio Inc METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING TYPE 1 DIABETES

Also Published As

Publication number Publication date
CN117794572A (zh) 2024-03-29
EP4347021A4 (en) 2025-04-23
IL308627A (en) 2024-01-01
US20220372146A1 (en) 2022-11-24
EP4347021A1 (en) 2024-04-10
WO2022251258A1 (en) 2022-12-01
KR20240023522A (ko) 2024-02-22
JP2024521164A (ja) 2024-05-28
MX2023013849A (es) 2023-12-08
CA3219473A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
US12565529B2 (en) Methods for treating type 1 diabetes
US20250304688A1 (en) Methods and Compositions Comprising Anti-CD3 Antibodies and DYRK1A Inhibitors for Treating Diabetes
US20220372146A1 (en) Methods for treating post infectious autoimmune diabetes
US20260008850A1 (en) Methods for delaying onset of type 1 diabetes
WO2024182767A1 (en) Methods and compositions for treating type 1 diabetes comprising teplizumab and verapamil
US12006366B2 (en) Methods and compositions for preventing type 1 diabetes
WO2024206739A1 (en) Methods for reducing exogenous insulin use
AU2025252600A1 (en) Methods and compositions for preventing or delaying type 1 diabetes
US20230382993A1 (en) Methods and compositions for preventing or delaying type 1 diabetes
WO2025024848A1 (en) Methods for treating type 1 diabetes
CN117940162A (zh) 用于治疗糖尿病的包含抗cd3抗体和dyrk1a抑制剂的方法和组合物
CN118591558A (zh) 用于预防或推迟第1型糖尿病的方法及组合物
EP4164689A2 (en) Methods and compositions for preventing type 1 diabetes